GILD presented detailed “Stribild TAF”-vs-Stribild data from two phase-3 trials at CROI: http://finance.yahoo.com/news/gilead-announces-phase-3-results-000500999.html GILD reported in Sep 2014 that these trials hit their non-inferiority endpoint (#msg-106558452).